Literature DB >> 10381371

Hepatocyte growth Factor/Scatter factor (HGF/SF) is a regulator of fibronectin splicing in MDCK cells: comparison between the effects of HGF/SF and TGF-beta1 on fibronectin splicing at the EDA region.

T Inoue1, K Nabeshima, Y Shimao, M Koono.   

Abstract

EDA-containing fibronectin (EDA + FN) is selectively produced under several physiological and pathological conditions requiring tissue remodeling, where cells actively proliferate and migrate. Only a few growth factors, such as transforming growth factor (TGF)-beta1, have been reported to regulate FN splicing at the EDA region. In the present study, we showed for the first time that hepatocyte growth factor/scatter factor (HGF/SF), which is mainly produced by mesenchymal cells and functions as a motogenic and mitogenic factor for epithelial cells, modulates FN splicing at the EDA region in MDCK epithelial cells. HGF/SF treatment increased the ratio of EDA + FN mRNA to mRNA of FN that lacks EDA (EDA - FN) (EDA+/EDA- ratio) more than TGF-beta1 treatment did: at a range from 0.02 to 20 ng/ml, HGF/SF increased the ratio in a dose-dependent manner by up to 2. 1-fold compared with nontreated control, while TGF-beta1 stimulated the EDA+/EDA- ratio by 1.5-fold at the optimum dose of 10 ng/ml. However, TGF-beta1 increased total FN mRNA levels by 3-fold at 10 ng/ml, but HGF/SF did not. We previously demonstrated that fibroblasts cultured at low cell density expressed more EDA + FN than those at high cell density. The same effect of cell density was also observed in MDCK cells. Furthermore, at low cell density, HGF/SF stimulated EDA inclusion into FN mRNA more effectively than did TGF-beta1, whereas at high cell density, TGF-beta1 was more potent than HGF/SF. Simultaneous treatment of cells with HGF/SF and TGF-beta1 synergistically stimulated EDA inclusion into FN mRNA. This stimulation of EDA inclusion into FN mRNA by HGF/SF led to increased EDA + FN protein production and secretion by cells, which was demonstrated by immunoblotting. Thus, our studies have shown that HGF/SF is an enhancer of EDA inclusion into FN mRNA as is TGF-beta1. However, these two factors were different in their effects at low and high cell densities and also in their effects on total FN mRNA levels. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10381371     DOI: 10.1006/bbrc.1999.0881

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  5 in total

1.  Fibronectin extra domain-A promotes hepatic stellate cell motility but not differentiation into myofibroblasts.

Authors:  Abby L Olsen; Bridget K Sackey; Cezary Marcinkiewicz; David Boettiger; Rebecca G Wells
Journal:  Gastroenterology       Date:  2011-12-24       Impact factor: 22.682

2.  EDA Fibronectin in Keloids Create a Vicious Cycle of Fibrotic Tumor Formation.

Authors:  Rhiannon M Kelsh; Paula J McKeown-Longo; Richard A F Clark
Journal:  J Invest Dermatol       Date:  2015-07       Impact factor: 8.551

3.  Transforming growth factor-beta1 regulates fibronectin isoform expression and splicing factor SRp40 expression during ATDC5 chondrogenic maturation.

Authors:  Fei Han; James R Gilbert; Gerald Harrison; Christopher S Adams; Theresa Freeman; Zhuliang Tao; Raihana Zaka; Hongyan Liang; Charlene Williams; Rocky S Tuan; Pamela A Norton; Noreen J Hickok
Journal:  Exp Cell Res       Date:  2007-02-28       Impact factor: 3.905

4.  Transforming growth factor-beta 1 induces intestinal myofibroblast differentiation and modulates their migration.

Authors:  Julia Brenmoehl; Sandra-Nicole Miller; Claudia Hofmann; Daniela Vogl; Werner Falk; Jürgen Schölmerich; Gerhard Rogler
Journal:  World J Gastroenterol       Date:  2009-03-28       Impact factor: 5.742

5.  Identification of splice regulators of fibronectin-EIIIA and EIIIB by direct measurement of exon usage in a flow-cytometry based CRISPR screen.

Authors:  Jessica A Hensel; Brent D Heineman; Amy L Kimble; Evan R Jellison; Bo Reese; Patrick A Murphy
Journal:  Sci Rep       Date:  2021-10-06       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.